IART Q2 2024 Earnings — Integra LifeSciences Holdings Corporation Revenue & Financial Results | Market Cap Arena

IARTIntegra LifeSciences Holdings Corporation

$738M

Q2 2024 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$418M+9.7% YoY

Gross Profit

$226M54.0% margin

Operating Income

-$3M-0.7% margin

Net Income

-$12M-3.0% margin

EPS (Diluted)

$-0.16

QoQ Revenue Growth

+13.4%

Cash Flow

Operating Cash Flow

$40M

Free Cash Flow

$11M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$4.1B

Total Liabilities

$2.5B

Stockholders' Equity

$1.5B

Cash & Equivalents

$215M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$418M	$381M	+9.7%
Gross Profit	$226M	$207M	+9.1%
Operating Income	-$3M	$13M	-124.2%
Net Income	-$12M	$4M	-396.4%

Revenue Segments

Codman Specialty Surgical

$302M72%

Tissue Technologies

$116M28%

Geographic Segments

UNITED STATES

$310M74%

Asia Pacific

$46M11%

Europe

$41M10%

Rest Of World

$21M5%